Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Wound Complication Rates After Vulvar Excisions for Premalignant Lesions.

Mullen MM, Merfeld EC, Palisoul ML, Massad LS, Woolfolk C, Powell MA, Mutch DG, Thaker PH, Hagemann AR, Kuroki LM.

Obstet Gynecol. 2019 Apr;133(4):658-665. doi: 10.1097/AOG.0000000000003185.

PMID:
30870300
2.

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.

PMID:
30478151
3.

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.

4.

Identification of molecular targets in vulvar cancers.

Palisoul ML, Mullen MM, Feldman R, Thaker PH.

Gynecol Oncol. 2017 Aug;146(2):305-313. doi: 10.1016/j.ygyno.2017.05.011. Epub 2017 May 20.

PMID:
28536037

Supplemental Content

Loading ...
Support Center